36 -7 (93) 2026 - Rustamov U.M., Azimova S.B. - RELATIONSHIP BETWEEN PROSTATE-SPECIFIC ANTIGEN LEVELS AND METABOLIC SYNDROME IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA AND PROSTATE CANCER

RELATIONSHIP BETWEEN PROSTATE-SPECIFIC ANTIGEN LEVELS AND METABOLIC SYNDROME IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA AND PROSTATE CANCER

Rustamov U.M. - Andijan State Medical Institute

Azimova S.B. - Tashkent State Medical University

Resume

Prostate-specific antigen (PSA) is the most widely used biomarker for the diagnosis, risk assessment, and clinical monitoring of benign prostatic hyperplasia (BPH) and prostate cancer (PCa). Nevertheless, serum PSA concentrations are influenced not only by pathological changes in the prostate gland but also by systemic metabolic abnormalities. Metabolic syndrome, characterized by central obesity, impaired glucose metabolism, dyslipidemia, and arterial hypertension, has been increasingly recognized as an important modifier of prostate physiology through its effects on chronic inflammation, insulin resistance, oxidative stress, and hormonal imbalance. These metabolic disturbances may alter PSA secretion and reduce the diagnostic accuracy of PSA-based screening, thereby complicating the early detection and clinical evaluation of prostate diseases. However, the relationship between serum PSA levels and metabolic syndrome in patients with BPH and PCa remains incompletely understood. The present study aimed to evaluate the association between serum prostate-specific antigen levels and metabolic syndrome in patients with benign prostatic hyperplasia and prostate cancer by analyzing clinical, anthropometric, and biochemical characteristics. The study included patients diagnosed with BPH, patients with histologically confirmed prostate cancer, and an age-matched healthy control group. Clinical evaluation comprised body mass index, waist circumference, systolic and diastolic blood pressure, fasting plasma glucose, serum triglycerides, high-density lipoprotein cholesterol, prostate volume measured by transrectal ultrasonography, and serum PSA concentration. Comparative statistical analyses were performed to determine the relationship between metabolic syndrome components and PSA levels in different study groups.

Keywords: prostate-specific antigen, metabolic syndrome, benign prostatic hyperplasia, prostate cancer, obesity, dyslipidemia, insulin resistance, prostate volume, biomarkers, risk assessment.

First page

246

Last page

252

For citation:Rustamov U.M., Azimova S.B. - RELATIONSHIP BETWEEN PROSTATE-SPECIFIC ANTIGEN LEVELS AND METABOLIC SYNDROME IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA AND PROSTATE CANCER//New Day in Medicine 7(93)2026 246-252 https://newdayworldmedicine.com/en/new_day_medicine/7-93-2026

List of References

1. European Association of Urology. EAU Guidelines on Prostate Cancer 2025. Arnhem (The Netherlands): European Association of Urology; 2025.
2. European Association of Urology. EAU Guidelines on Management of Non-neurogenic Male Lower Urinary Tract Symptoms, including Benign Prostatic Obstruction 2025. Arnhem (The Netherlands): European Association of Urology; 2025.
3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2025;75(1):15-48.
4. Mottet N, Cornford P, van den Bergh RCN, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Eur Urol. 2025;87(2):123-170.
5. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-1645. doi:10.1161/CIRCULATIONAHA.109.192644
6. Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep. 2018;20(2):12. doi:10.1007/s11906-018-0812-z
7. Grundy SM. Metabolic syndrome update. Trends Cardiovasc Med. 2024;34(2):87-95.
8. Yassin AA, Haider A, Haider KS, et al. Metabolic syndrome, testosterone deficiency and prostate disease: current evidence and clinical implications. World J Mens Health. 2023;41(2):181-197. doi:10.5534/wjmh.220174
9. Gacci M, Corona G, Vignozzi L, et al. Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. BJU Int. 2022;129(5):561-572. doi:10.1111/bju.15631
10. Kim EH, Larson JA, Andriole GL. Management of benign prostatic hyperplasia. Annu Rev Med. 2023;74:137-152. doi:10.1146/annurev-med-043021-033146

    file

    download